Kodiak Sciences Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Kodiak reported Q2 2026 net loss of $65.6M ($1.05/share) on $56.1M R&D spend. Cash position $125.9M (down from $209.9M at year-end 2025), expected to support operations into 2027. Three Phase 3 milestones on track: DAYBREAK (Zenkuda/KSI-501 in wet AMD) topline September 2026; PEAK Pivotal Analysis 1 (KSI-101 in MESI) December 2026; ALTO enrollment (KSI-501 in DME) ongoing. No counterparties, financing, or strategic deals disclosed.
Why this rating
Routine quarterly earnings. Cash burn ($65.6M/quarter, $123.8M YTD) materially erodes $125.9M position. Clinical milestones are expected/on-track, not surprises. No transformational event or capital event. Company is pre-commercial.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.